Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.53 |
| ▸ | MGAT2 | Q10469 | 6/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566287 | 1.00 | ESR1 (0.53) | ESR1MGAT2NR1I2NR3C1PGR | |
| SCHEMBL5855586 | 1.00 | ESR1 (0.53) | ESR1MGAT2NR1I2NR3C1PGR | |
| SCHEMBL8193491 | 0.90 | ESR1 (0.45) | ESR1MGAT2 | |
| SCHEMBL5855444 | 0.90 | ESR1 (0.45) | ESR1MGAT2 | |
| SCHEMBL5855925 | 0.87 | ESR1 (0.40) | ESR1MGAT2NR1I2NR3C1PGR | |
| SCHEMBL5857490 | 0.81 | NR5A1 (0.37) | ESR1ESR2 | |
| SCHEMBL5854398 | 0.80 | ESR1 (0.64) | ESR1MGAT2NR1I2NR3C1PGR | |
| SCHEMBL5856106 | 0.78 | ESR1 (0.53) | ESR1MGAT2NR1I2NR3C1PGR | |
| SCHEMBL6568118 | 0.72 | ESR1 (0.53) | ESR1MGAT2 | |
| SCHEMBL5855988 | 0.70 | ESR1 (0.45) | ESR1MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074829-B2 | Antiestrogens, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20030162830-A1 | New antiestrogens, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162830-A1 | New antiestrogens, process for their production and their pharmaceutical use | CYP19A1, NR5A1, HSD17B11 | ESR1 6/4885MGAT2 532/4885NR1I2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.